不同激素受体作为乳腺癌预后标志物的研究进展

doi:10.3969/j.issn.1006-7795.2018.04.001

首都医科大学学报 ›› 2018, Vol. 39 ›› Issue (4): 479-485.doi: 10.3969/j.issn.1006-7795.2018.04.001

不同激素受体作为乳腺癌预后标志物的研究进展

张颖¹, 阮祥燕^1,2, 蔡桂举¹, 苏雅洁³, 李娜⁴, Alfred O. Mueck^1,2

1. 首都医科大学附属北京妇产医院内分泌科, 北京 100026;
2. 德国图宾根大学妇产医院妇女健康部与妇女健康研究中心, 图宾根 D-72076, 德国;
3. 北京市顺义区妇幼保健院, 北京儿童医院顺义妇儿医院病理科, 北京 101300;
4. 北京市顺义区妇幼保健院, 北京儿童医院顺义妇儿医院检验科, 北京 101300

收稿日期:2018-05-31 出版日期:2018-07-21 发布日期:2018-07-21
通讯作者: 阮祥燕 E-mail:ruanxiangyan@163.com
基金资助:
国家自然科学基金（81671411），北京市自然科学基金（7162062），北京市属医院科研培育项目（PX2016051），首都医科大学附属北京妇产医院中青年学科骨干培养专项（fcyy201619）。

Different hormone receptors and their roles as prognostic markers in breast cancer

Zhang Ying¹, Ruan Xiangyan^1,2, Cai Guiju¹, Su Yajie³, Li Na⁴, Alfred O. Mueck^1,2

1. Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China;
2. Department for Women's Health, University Women's Hospital and Research Center for Women's Health, University of Tuebingen, Tuebingen D-72076, Germany;
3. Department of Pathology, Shunyi Maternal and Children's Hospital of Beijing Children's Hospital, Beijing 101300, China;
4. Laboratory Department, Shunyi Maternal and Children's Hospital of Beijing Children's Hospital, Beijing 101300, China

Received:2018-05-31 Online:2018-07-21 Published:2018-07-21
Supported by:
This study was supported by National Natural Science Foundation of China (81671411); Natural Science Foundation of Beijing (7162062); Beijing Municipal Administration of Hospitals Incubating program (PX2016051);Beijing Obstetrics and Gynecology Hospital, Gapitai Medicsl University (fcyy201619).

摘要/Abstract

摘要： 乳腺癌是导致女性死亡的主要病因之一，因此现在对于相关标志物及治疗靶位点的研究非常重要。不同亚型乳腺癌其药物治疗反应及远期预后是不同的。例如三阴性乳腺癌雌激素受体-α（estrogen receptor-α，ER-α），孕激素受体（progesterone receptor，PR），人类表皮生长因子受体-2（human epidermal growth factor receptor-2，HER-2）均为阴性，完全缺乏可用的生物标志物来评估预后，其治疗反应也较差。近年来体内外实验结果表明，孕激素受体膜组分1（progesterone receptor membrane component 1，PGRMC1）在乳腺癌的发生发展过程中起着重要作用。那么不同激素受体在乳腺癌发展及预后中的预测作用如何，PGRMC1是否有可能成为新型乳腺癌预后标志物?在本篇综述中，将针对这一系列问题进行阐述。

关键词: 乳腺癌, 孕激素受体膜组分1, 预后标志物

Abstract: Breast cancer is one of the leading causes of death in women,and there is an urgent need for new biomarkers and therapeutic targets.The drug treatment response and long-term prognosis of various breast cancer subtypes are different. In cases like triple negative breast cancer estrogen receptor-α(ER-α), progesterone receptor(PR), and human epidermal growth factor receptor-2 (HER-2), there is a complete lack of available biomarkers for prognosis,and therapeutic response is poor. In recent years, in vitro and in vivo experiments have shown that progesterone receptor membrane component 1 (PGRMC1) plays an important role in the occurrence and development of breast cancer. So how do different hormone receptors predict the development and prognosis of breast cancer? Will PGRMC1 be a new potential prognostic marker for breast cancer in the future? We will review the results of related researches.

Key words: breast cancer, progesterone receptor membrane component 1 (PGRMC1), prognostic markers

中图分类号:

R711

张颖, 阮祥燕, 蔡桂举, 苏雅洁, 李娜, Alfred O. Mueck. 不同激素受体作为乳腺癌预后标志物的研究进展[J]. 首都医科大学学报, 2018, 39(4): 479-485.

Zhang Ying, Ruan Xiangyan, Cai Guiju, Su Yajie, Li Na, Alfred O. Mueck. Different hormone receptors and their roles as prognostic markers in breast cancer[J]. Journal of Capital Medical University, 2018, 39(4): 479-485.

参考文献

[1] Foulkes W D, Smith I E, Reis-Filho J S. Triple-negative breast cancer[J]. N Engl J Med,2010,363(20):1938-1948.
[2] Dent R, Trudeau M, Pritchard K I, et al. Triple negative breast cancer:clinical features and patterns of recurrence[J]. Clin Cancer Res, 2007,13(15 Pt1):4429-4434.
[3] 张颖, 阮祥燕, 米鑫,等. 孕激素受体膜组分1(PGRMC1)对预测乳腺癌预后作用的研究[J]. 首都医科大学学报,2015,36(4):548-552.
[4] Frasor J, Danes J M, Komm B, et al.Profiling of estrogen up-and down-regulated gene expression in human breast cancer cells:insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype[J]. Endocrinology,2003, 144(10):4562-4574.
[5] Heldring N, Pike A, Andersson S, et al. Estrogen receptors:how do they signal and what are their targets[J]. Physiol Rev,2007,87(3):905-931.
[6] Vrtacnik P, Ostanek B, Mencej-Bedrac S, et al. The many faces of estrogen signaling[J]. Biochem Med (Zagreb),201424(3):329-342.
[7] Jensen E V, Jordan V C. The estrogen receptor:a model for molecular medicine[J]. Clin Cancer Res,2003, 9(6):1980-1989.
[8] Hewitt S C, Korach K S. Estrogen receptors:structure, mechanisms and function[J]. Rev Endocr Metab Disord,2002,3(3):193-200.
[9] Albanito L, Lappano R, Madeo A, et al.G-protein-coupled receptor 30 and estrogen receptor-alpha are involved in the proliferative effects induced by atrazine in ovarian cancer cells[J]. Environ Health Perspect,2008,116(12):1648-1655.
[10] Mehta R G, Hawthorne M, Mehta R R, et al. Differential roles of ER-α and ER-β in normal and neoplastic development in the mouse mammary gland[J]. PLoS One, 2014, 9(11):e113175.
[11] Stope M B, Popp S L, Knabbe C, et al. Estrogen receptor alpha attenuates transforming growth factor-beta signaling in breast cancer cells independent from agonistic and antagonistic ligands[J]. Breast Cancer Res Treat,2010,120(2):357-367.
[12] Taylor A H, Al-Azzawi F. Immunolocalisation of oestrogen receptor beta in human tissues[J]. J Mol Endocrinol,2000, 24(1):145-155.
[13] Carroll J S, Brown M. Estrogen receptor target gene:an evolving concept[J]. Mol Endocrinol, 2006,20(8):1707-1714.
[14] Kastner P, Krust A, Turcotte B, et al. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B[J]. EMBO J,1990,9(5):1603-1614.
[15] Soyal S, Ismail P M, Li J, et al. Progesterone's role in mammary gland development and tumorigenesis as disclosed by experimental mouse genetics[J]. Breast Cancer Res,2002, 4(5):191-196.
[16] Conneely O M, Mulac-Jericevic B, Lydon J P. Progesterone-dependent regulation of female reproductive activity by two distinct progesterone receptor isoforms[J].Steroids,2003, 68(10-13):771-778.
[17] Mulac-Jericevic B, Lydon J P, DeMayo F J,et al. Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform[J]. Proc Natl Acad Sci U S A,2003,100(7):9744-9749.
[18] Richer J K, Jacobsen B M, Manning N G, et al. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells[J]. J Biol Chem,2002,277(7):5209-5218.
[19] Hopp T A, Weiss H L, Hilsenbeck S G, et al. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates[J]. Clin Cancer Res, 2004, 10(8):2751-2760.
[20] Cahill M A. Progesterone receptor membrane component 1:an integrative review[J]. J Steroid Biochem Mol Biol, 2007,105:16-36.
[21] Jeng M H, Parker C J, Jordan V C.Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation[J].Cancer Res,1992,52(23):6539-6546.
[22] Neubauer H, Ruan X, Schneck H.Overexpression of progesterone receptor membrane component 1:possible mechanism for increased breast cancer risk with norethisterone in hormone therapy[J].Menopause,2013,20(5):504-510.
[23] Ruan X,Neubauer H,Yang Y. Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells[J].Climacteric,2012,15(5):467-472.
[24] AIRTUM Working Group, CCM, AIEOP Working Group. Italian cancer figures, report 2012:cancer in children and adolescents[J]. Epidemiol Prev,2013,37(1 Suppl 1):1-225.
[25] McDonnell D P, Chang C Y, Nelson E R. The estrogen receptor as a mediator of the pathological actions of cholesterol in breast cancer[J].Climacteric, 2014,17 Suppl 2:60-65.
[26] Kuiper G G, Carlsson B, Grandien K,et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta[J]. Endocrinology, 1997, 138(3):863-870.
[27] Guo L, Meng J, Yilamu D, et al. Significance of ER-β expression in different molecular subtypes of breast cancer[J]. Diagn Pathol,2014,9:20.
[28] Ignatiadis M, Sotiriou C. Luminal breast cancer:from biology to treatment[J]. Nat Rev Clin Oncol,2013,10(9):494-506.
[29] Skliris G P, Leygue E, Curtis-Snell L, et al. Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours[J]. Br J Cancer,2006,95(5):616-626.
[30] Yan Y, Li X, Blanchard A, et al. Expression of both estrogen receptor-beta 1(ER-β1) and its co-regulator steroid receptor RNA activator protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with estrogen receptor-alpha (ER-α)-negative early breast cancer (EBC)[J]. Ann Oncol,2013,24(8):1986-1993.
[31] Liu J, Guo H, Mao K,et al. Impact of estrogen receptor-β expression on breast cancer prognosis:a meta-analysis[J]. Breast Cancer Res Treat,2016,156(1):149-162.
[32] Wu X, Subramaniam M, Grygo S B,et al. Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen[J]. Breast Cancer Res,2011,13(2):R27.
[33] Elebro K, Borgquist S, Simonsson M,et al. Combined androgen and estrogen receptor status in breast cancer:treatment prediction and prognosis in a population-based prospective cohort[J]. Clin Cancer Res,2015,21(16):3640-3650.
[34] Cui X, Schiff R, Arpino G, et al. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy[J]. J Clin Oncol,2005,23(30):7721-7735.
[35] Bardou V J, Arpino G, Elledge R M, et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases[J]. J Clin Oncol,2003,21(10):1973-1979.
[36] Bae S Y, Kim S, Lee J H, et al. Poor prognosis of single hormone receptor-positive breast cancer:similar outcome as triple-negative breast cancer[J]. BMC Cancer,2015,15:138.
[37] Yang L H, Tseng H S, Lin C, et al. Survival benefit of tamoxifen in estrogen receptor-negative and progesterone receptor-positive low grade breast cancer patients[J]. J Breast Cancer,2012, 15(3):288-295.
[38] Richer J K, Jacobsen B M, Manning N G, et al. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells[J]. J Biol Chem,2002, 277(7):5209-5218.
[39] Bamberger A M, Milde-Langosch K, Schulte H M, et al. Progesterone receptor isoforms, PR-B and PR-A, in breast cancer:correlations with clinicopathologic tumor parameters and expression of AP-1 factors[J]. Horm Res, 2000, 54(1):32-37.
[40] 杜娟,阮祥燕.三阴乳腺癌的特点及研究进展[J].首都医科大学学报,2015,36(4):578-582.
[41] 郑红梅,李祥,金立亭,等.三阴性乳腺癌基因学分子分型和个体化治疗新进展[J].中华肿瘤防治杂志, 2016,23(17):1198-1204.
[42] Aydiner A, Sen F, Tambas M,et al. Metaplastic breast carcinoma versus triple-negative breast cancer:survival and response to treatment[J].Medicine (Baltimore),2015,94(52):e2341.
[43] Neubauer H,Yang Y, Seeger H, et al. The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells[J].Menopause,2011,18(8):845-850.
[44] Neubauer H, Chen R, Schneck H, et al.Membrane-initiated effects of progestogens on proliferation and downstream signal cascades in MCF-7 breast cancer cells[J].Horm Mol Biol Clin Investig,2011,6(1):185-192.
[45] Zhang Y, Ruan X, Willibale M, et al. May progesterone receptor memebrane component 1(PGRMC1) predict the risk of breast cancer?[J].Gynecol Endocrinol, 2016,32(1):58-60.
[46] 王利娟,阮祥燕,赵越.PGRMC1在乳腺癌组织中的表达及其与临床病理特征的相关性[J].首都医科大学学报,2018,39(2):272-276.
[47] Thomas P, Pang Y, Dong J. Enhancement of cell surface expression and receptor functions of membrane progestin receptor α (mPRα) by progesterone receptor membrane component 1(PGRMC1):evidence for a role of PGRMC1 as an adaptor protein for steroid receptors[J]. Endocrinology, 2014,155(3):1107-1119.
[48] Peluso J J,Pappalardo A,Losel R,et al.Expression and function of PAIRBP1 within gonadotropin-primed immature rat ovaries:PAIRBP1 regulation of granulosa and luteal cell viability[J].Biol Reprod,2005,73(2):261-270.
[49] Crudden G, Chitti R E, Craven R J.Hpr6(heme-1 domain protein) regulates the susceptibility of cancer cells to chemotherapeutic drugs[J].J Pharmacol Exp Ther, 2006,316(1):448-455.
[50] Ruan X, Zhang Y, Mueck A O, et al. Increased expression of progesterone receptor memebrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and negative breast cancer[J].Menopause,2017,24(2):203-209.
[51] Clark N C, Friel A M, Pru C A, et al. Progesterone receptor membrane component 1 promotes survival of human breast cancer cells and the growth of xenograft tumors[J]. Cancer Biol Ther, 2016,17(3):262-271.
[52] Gnant M, Thomssen C, Harbeck N. St. Gallen/Vienna 2015:a brief Summary of the consensus discussion[J]. 2015,10(2):124-130.
[53] Otsuka I, Takahashi S, O'uchi K, et al.Clinicopathological features of endometrial carcinoma in tamoxifen-and toremifene-treated breast cancer patients[J].Gan To Kagaku Ryoho,2010,37(2):279-283.
[54] Leung F, Terzibachian J J, Govyadovskiy A, et al.Tamoxifen in the adjuvant setting for breast cancer:reflexions about the risk of uterine carcinosarcoma[J]. Gynecol Obstet Fertil,2009,37(5):447-451.
[55] Heikinheimo O, Gemzell-Danielsson K. Emerging indications for the levonorgestrel-releasing intrauterine system (LNG-IUS)[J]. Acta Obstet Gynecol Scand,2012,91(1):3-9.
[56] Depypere H, Inki P. The levonorgestrel-releasing intrauterine system for endometrial protection during estrogen replacement therapy:a clinical review[J]. Climacteric, 2015,18(4):470-482.
[57] Dominick S, Hickey M, Chin J,et al. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen[J]. Cochrane Database Syst Rev,2015,(12):CD007245.
[58] Trinh X B, Tjalma W A, Makar A P, et al. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients[J]. Fertil Steril,2008,90(1):17-22.
[59] Fu Y, Zhuang Z.Long-term effects of levonorgestrel-releasing intrauterine system on tamoxifen-treated breast cancer patients:a meta-analysis[J].Int J Clin Exp Pathol,2014,7(10):6419-6429.

不同激素受体作为乳腺癌预后标志物的研究进展

Different hormone receptors and their roles as prognostic markers in breast cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	赵越, 阮祥燕, 程姣姣, 谷牧青, 许新, 王月姣. 乳腺癌中PGRMC1表达与临床病理参数的相关性[J]. 首都医科大学学报, 2022, 43(3): 350-356.
[2]	魏常胜, 骆成玉, 张树琦. 环乳晕切口联合乳腔镜腋窝淋巴结清扫在早期乳腺癌保乳手术中的应用[J]. 首都医科大学学报, 2021, 42(6): 1014-1020.
[3]	中华预防医学会妇女保健分会; 中国人体健康科技促进会妇科内分泌与生育力促进专委会. 乳腺癌患者选择性雌激素受体调节剂治疗相关子宫内膜安全管理的中国专家共识(2021版)[J]. 首都医科大学学报, 2021, 42(4): 672-677.
[4]	阮祥燕, 杨瑜, 卢丹, 杜娟, 程姣姣, 谷牧青, 李扬璐, 金凤羽, 段微, 代荫梅, 鞠蕊, 许新, MatthiasKorell, AlfredO.Mueck. 中国首例乳腺癌患者冻存卵巢组织移植成功报道及文献复习[J]. 首都医科大学学报, 2021, 42(2): 177-182.
[5]	杨阳, 康骅, 赵菁, 凌煜玮, 赵烨, 王亚军, 戎冬冬. 术前乳腺MRI对乳腺癌保乳手术切缘评估的回顾性分析[J]. 首都医科大学学报, 2020, 41(6): 943-953.
[6]	王爱婷, 鄢丹, 齐宪荣. 包载多西他赛的聚合物胶束抑制小鼠乳腺癌转移作用研究[J]. 首都医科大学学报, 2020, 41(2): 225-230.
[7]	王维, 张紫寒, 翟妍, 桑翠琴, 王淑珍. 子宫体、乳腺双原发癌的临床病理特征[J]. 首都医科大学学报, 2019, 40(6): 857-862.
[8]	张蕴显, 王雅梅, 周萍. 乳腺癌中基于开放染色质的环状RNA互作网络构建及功能分析[J]. 首都医科大学学报, 2019, 40(6): 901-910.
[9]	白向东, 郝雅婷, 张欣雪, 贺强. 脾多肽注射液联合术后化疗对三阴性乳腺癌患者临床疗效的研究[J]. 首都医科大学学报, 2019, 40(6): 911-915.
[10]	张凌燕, 阮祥燕, 蔡桂举, 谷牧青, Alfred O. Mueck. 他莫昔芬治疗转染孕激素受体膜组分1乳腺癌裸鼠模型对乳腺肿瘤组织Ki-67表达的影响[J]. 首都医科大学学报, 2019, 40(4): 533-538.
[11]	王月姣, 阮祥燕, 谷牧青, 蔡桂举, 李雪, 张凌燕, Alfred O. Mueck. 他莫昔芬治疗乳腺癌异种移植瘤裸鼠子宫病理改变[J]. 首都医科大学学报, 2019, 40(4): 539-543.
[12]	白向东, 郝雅婷, 张欣雪, 贺强. 雌激素受体阳性和阴性乳腺癌术后辅助化学药物治疗中加用脾多肽的临床免疫疗效观察[J]. 首都医科大学学报, 2019, 40(3): 443-448.
[13]	陈妮娜, 范怡畅, 尚昆, 杨婧, 曹邦伟. 血清血脂及载脂蛋白浓度与乳腺癌分子分型及Ki-67表达水平的相关性研究[J]. 首都医科大学学报, 2019, 40(2): 191-194.
[14]	李雪, 阮祥燕, 谷牧青, 蔡桂举, 赵越, Alfred O. Meuck. 孕激素受体膜组分1促进雌孕激素诱导的乳腺癌细胞增生的研究——雌二醇与周期序贯及连续联合比较[J]. 首都医科大学学报, 2019, 40(2): 237-243.
[15]	徐泉, 刘玉洁, 潘钰, 郑秀瑗, 刘静民, 孙小花, 邹丽丽, 马丽娜, 严红松. 生物电阻抗测试频率对乳腺癌相关淋巴水肿定量评估的影响[J]. 首都医科大学学报, 2018, 39(5): 747-751.